Previous close | 1.2120 |
Open | 1.2220 |
Bid | 1.1760 x 0 |
Ask | 1.2360 x 0 |
Day's range | 1.2120 - 1.2220 |
52-week range | 1.0990 - 4.1960 |
Volume | |
Avg. volume | 3,193 |
Market cap | 136.792M |
Beta (5Y monthly) | 1.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9300 |
Earnings date | 29 July 2024 - 02 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Confer
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions
Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May